Miraculins Announces Grant Of Options

WINNIPEG, MANITOBA--(Marketwired - Dec 3, 2014) - Miraculins Inc. (TSX VENTURE:MOM), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces that it has granted an aggregate of 1,500,000 stock options at an exercise price of $0.10 per common share, to certain directors, officers, employees, consultants and management company employees of the Company. The options are set to expire five years from the date of grant and are subject to the approval of the TSX Venture Exchange and the terms of Miraculins' stock option plan. In accordance with securities regulatory requirements, any shares issued pursuant to the exercise of such options will be subject to a resale restriction for a period of four months from the date of grant of the underlying option.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.